CliffBio
small molecule

LENALIDOMIDE

LENALIDOMIDE

Loss of exclusivity—loss of exclusivity
CompanyLupin →See this company's full patent-cliff portfolio

Drug detail

Brand nameLENALIDOMIDE
Active ingredientLENALIDOMIDE
Strength15MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2025
Marketing statusRX

More from Lupin

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.